CJC-1295 with DAC 2mg (Euro-Pharmacies, Europe)

Manufacturer: Euro-Pharmacies, Europe

Pharmaceutical name: Drug Affinity Complex: Growth Hormone-Releasing Factor

Pack: 1 vial (2 mg)

CJC-1295 peptide with DAC, also referred to as DAC:GRF, is a synthetic replica of part of the naturally occurring growth hormone releasing hormone (GHRH). The chemical composition of CJC-1295 with DAC is centered around the first 29 amino acids of endogenous GHRH, as these initial amino acids are crucial for complete biological activity.

 

This peptide has undergone additional modifications by changing four amino acids to enhance its stability and effectiveness compared to the earlier version of CJC-1295 without DAC. These modifications help the peptide to bind permanently to the protein albumin within the body, decreasing its degradation and oxidation, which boosts its stability. Additionally, these extra amino acids improve the binding affinity to the GHRH receptor, thereby enhancing its potency. GHRH is essential for the natural secretion of growth hormone and is required for achieving optimal growth during development.

 

CJC-1295 operates by triggering the secretion of growth hormone through binding to GHRH receptors, leading to the release of all types of growth hormone peptides typically secreted by the pituitary gland. These hormones can promote increases in bone density and collagen production, strengthen the immune system, and stimulate the growth of lean muscle mass.

 

CJC-1295 with DAC can be used in conjunction with growth hormone releasing peptides for improved peptide cycling results. It is often paired with growth hormone replacement peptides (GHRP) such as GHRP-6 or GHRP-2. The combined administration of CJC-1295 DAC with GHRPs can expedite fat loss and weight reduction while promoting anabolic effects through growth hormone-induced fat breakdown. In summary, CJC-1295 with DAC enhances protein synthesis and supports the development of lean muscle tissue. The peptide also aids in faster recovery from injuries, lowers body fat, and increases muscle mass. The growth-boosting traits of CJC-1295 DAC also encourage cell growth and division, improving skin health, healing, and immune system performance.

 

This peptide should not be mistaken for CJC-1295 without DAC, as their chemical characteristics differ significantly, impacting dosing. CJC-1295 DAC has a half-life of approximately 8 days post-injection. CJC-1295 with DAC should be administered subcutaneously, with injections occurring once a week at doses of 100 mcg or 200 mcg due to its prolonged half-life. This CJC-1295 DAC peptide cycling method will result in an extended overall increase in growth hormone. A weekly dose of CJC-1295 with DAC can be stacked with other GHRPs, such as GHRP-6 or GHRP-2.

 

Numerous studies have highlighted the growth-enhancing effects and safety of GHRH when given to children with growth hormone deficiencies. Various treatment protocols, including intravenous pulses, intranasal delivery, subcutaneous injections, and continuous infusion, have been evaluated, confirming that the growth-promoting impact of GHRH is linked to the dosage and frequency of administration. No unexpected adverse effects have been reported after extended treatment, regardless of how it was administered. However, some mild side effects, such as fatigue, euphoria (head rush), water retention, tingling, and numbness, may occur. Adhering to the recommended dosage helps minimize the potential for side effects.